4-Hydroxymethyl-piperidine-1-carboxylic acid 4-(3,3-dimethyl-butylcarbamoyl)-phenyl ester ester | 548769-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Hydroxymethyl-piperidine-1-carboxylic acid 4-(3,3-dimethyl-butylcarbamoyl)-phenyl ester ester
• 英文别名: [4-(3,3-Dimethylbutylcarbamoyl)phenyl] 4-(hydroxymethyl)piperidine-1-carboxylate
• CAS: 548769-42-2
• 化学式: C₂₀H₃₀N₂O₄
• 分子量: 362.469
• InChiKey: KHTIZAWSGXUEQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-哌啶甲醇 、 4-(3,3-dimethyl-butylcarbamoyl)-phenyl chloroformate 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-Hydroxymethyl-piperidine-1-carboxylic acid 4-(3,3-dimethyl-butylcarbamoyl)-phenyl ester ester
  参考文献：
  名称：

  Compounds and uses thereof for decreasing activity of hormone-sensitive lipase

  摘要：

  使用化合物抑制激素敏感性脂肪酶，包括这些化合物的药物组合物，使用这些化合物和组合物的治疗方法，以及新化合物。目前的化合物是激素敏感性脂肪酶的抑制剂，可能在治疗和/或预防需要降低激素敏感性脂肪酶活性的医学疾病中有用。

  公开号：

  US20030166644A1

文献信息

• COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE
  申请人：NOVO NORDISK A/S

  公开号：EP1458375A2

  公开（公告）日：2004-09-22
• [EN] COMPOUNDS AND USE THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE<br/>[FR] UTILISATION DE COMPOSES POUR REDUIRE L'ACTIVITE DE LA LIPASE HORMONO-SENSIBLE
  申请人：NOVO NORDISK AS

  公开号：WO2003051842A2

  公开（公告）日：2003-06-26

  Carbamates and related compounds of formula R1R2NCO-Y or R1R2NCS-Y wherein R1 and R2 may form a ring, are inhibitors of hormone sensitive lipase and are useful for the treatment of any disorder where it is desirable to modulate the plasma level of free fatty acids, glycerol, LDL-cholesterol, HDL-cholesterol, insulin and/or glucose; and or modulate intracellular triacylglycerol and cholesterol stores, intracellular level of fatty acids, fatty acid esters such as diacylglycerols, phosphatidic acids, long chain acyl-CoA’s as well as citrate or malonyl-CoA; and or increase insulin sensitivity; and or modulate insulin secretion from pancreatic beta cells. More particularly said disorders are selected from the group consisting of insulin resistance, diabetes type 1, hyperglycemia, dislipidemia, obesity, abnormalities of lipoprotein metabolism and any combinations thereof.